FDA cancels adcomm on Biohaven drug; Catalent lays off staff
Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.
Previous Post
Politicians demand watchdog investigation into controversial GP company
Next Post
GP practices in Scotland to receive extra £15m investment
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago